Cardiol Therapeutics Achieves 50% Patient Enrollment in Pivotal Phase III MAVERIC Trial
CRDL sits 27% above its 52-week low of $0.771.
Summary
Cardiol Therapeutics announced it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial for recurrent pericarditis, marking a key de-risking milestone for its lead drug candidate, CardiolRx™.
Key Events · Product Development and Regulatory · CRDL
-
50% Patient Enrollment Achieved
Cardiol Therapeutics has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis.
-
Key De-risking Milestone
This enrollment milestone represents a significant execution and risk-reduction inflection point for the company's lead registrational program.
-
Full Enrollment Expected Q2 2026
The company anticipates completing full patient enrollment in the MAVERIC trial by the second quarter of 2026.
-
Expanding Clinical Infrastructure
More than 15 leading cardiovascular centers in the U.S. are actively enrolling patients, with additional sites in Europe and Canada being activated to accelerate momentum.
Analysis · CRDL · Life Sciences
This milestone is highly significant for Cardiol Therapeutics as it de-risks the development timeline and increases the probability of success for its lead registrational program. Reaching 50% enrollment in a pivotal Phase III trial demonstrates strong operational execution and investigator confidence in CardiolRx™ for recurrent pericarditis, an underserved patient population. The company anticipates completing full enrollment in Q2 2026, which provides a clear path towards potential regulatory submission and commercialization.
At the time of this filing, CRDL was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96M. The 52-week trading range was $0.77 to $1.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.